IndraLab

Statements


| 2

reach
"Addition of Erlotinib inhibits transcriptional activation of IRF3 demonstrating that it is driven by EGFR."

reach
"In addition, there is a loss of erlotinib induced IRF3 transcriptional activity in multiple EGFR mutant cell lines in response to chemical or biological inhibition of TBK1 (XREF_FIG - XREF_FIG)."